Drug profile · INN
zanamivir
DECTOVA
zanamivir (DECTOVA) is a neuraminidase inhibitor. Route of administration: inhalation. Current US regulatory status: approved.
Drug details — zanamivir
- US status
- approved
- Class
- Antiinfectives for systemic use (J05)
- Route
- INHALATION
- Patents
- 0
- Programs
- 1
- Data quality
- 0.84
Quick answer
zanamivir (DECTOVA) is a neuraminidase inhibitor. Route of administration: inhalation. Current US regulatory status: approved.
Key facts
Mechanism of action
Neuraminidase inhibitor
Primary target: Neuraminidase
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is zanamivir?
zanamivir (DECTOVA) is a neuraminidase inhibitor. Route of administration: inhalation. Current US regulatory status: approved.
What is the brand name for zanamivir?
DECTOVA is a marketed brand name for zanamivir. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of zanamivir?
zanamivir has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.